03 November 2023 KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA 0 minute read Pharma/Biotech By Cate Swannell Previous Post Next Post